NCT01059786 · OUTCOME

Cluster of Differentiation 4 (CD4+) T-cells

Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia · Source last updated 2026-07-22

This outcome was registered, but no numerical results were posted in the captured record.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: 4 years

What was measured

Cluster of differentiation 4 (CD4+) T-cells assessed by analysis.

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

anticipated Posting Date: 2031-06
denom Units Selected: Participants
description: Cluster of differentiation 4 (CD4+) T-cells assessed by analysis.
reporting Status: NOT_POSTED
time Frame: 4 years
title: Cluster of Differentiation 4 (CD4+) T-cells
type: SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice